ADGRG6 and neoplasm: For detecting, ADGRG6 enhancer mutations were usually using Sanger sequencing or NGS, but these methods are time‐consuming or sensitivity‐limited, which may result in an underestimation of the prevalence of ADGRG6 enhancer mutations when tumor samples contain a low percentage of mutations.